In conclusion, in this study, we showed that SGLT2 inhibitor DAPA pretreatment attenuates myocardial hypertrophy, fibrosis and LV dysfunction in Ang II-infused rat model via negative regulation of TGF-β1/Smad signaling. Here, SLC5A2 is linked to cardiac hypertrophy.